Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
The University of Pennsylvania is teaming with Intel to lead a federation of more than two dozen medical and research centers on an AI system for identifying brain tumors.
Researchers in the U.K. and U.S. have developed an automatic prediction model that can tell if someone is infected with COVID-19 based on symptoms alone.
A convolutional neural network trained and internally validated on more than 15,000 lung CT scans has correctly reclassified indeterminate pulmonary nodules into low-risk or high-risk categories.
An AI algorithm has slightly outperformed neurologists at identifying or ruling out Alzheimer’s disease from MRI brain scans combined with demographic information and neuropsychological test results.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
